LivFul and Global Access Diagnostics (GAD) announced a new partnership to make a variety of diagnostic kits, starting with COVID-19 rapid antigen tests, available in Low to Middle-Income Countries.

The rapid COVID-19 antigen tests produced by GAD are known for sensitivity (90.6%) and specificity (100%). They can also be used in a nonlaboratory setup.

"GAD's mission is to work in partnership with governments, donor organizations, regional experts and the private sector to innovate in the technology and delivery of testing." says Mark Radford, Executive Director at Global Access Diagnostics. "LivFul is an ideal private sector partner to work with us to that end. We are aligned in driving access to our COVID-19 antigen test for as many people as possible."

"LivFul was founded to expand health access with products that transform lives and business models that reach all people. GAD takes a similar view as to how to ensure that people have access to quality, affordable health products." says Michael Norman, LivFul CEO. 

GAD is an independent social enterprise specializing in lateral flow diagnostics, with its own flexible, high-volume manufacturing capability. Developed in partnership with Mologic, a leading innovator in rapid diagnostic technology; their aim is to provide access to high quality, affordable diagnostics for everyone, driven by need not profit.